RT Journal Article SR Electronic T1 Adjusting COVID-19 seroprevalence survey results to account for test sensitivity and specificity JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.04.21252939 DO 10.1101/2021.03.04.21252939 A1 Mark J. Meyer A1 Shuting Yan A1 Samantha Schlageter A1 John D. Kraemer A1 Eli S. Rosenberg A1 Michael A. Stoto YR 2021 UL http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252939.abstract AB Population-based seroprevalence surveys can provide useful estimates of the number of individuals previously infected with SARS-CoV-2 and still susceptible as well as contribute to better estimates of the case fatality rate and other measures of COVID-19 severity. No serological test is 100% accurate, however, and the standard correction that epidemiologists use to adjust estimates relies on estimates of the test sensitivity and specificity often based on small validation studies. This paper develops a fully Bayesian approach to adjust observed prevalence estimates for sensitivity and specificity. Application to a seroprevalence survey conducted in New York State in 2020 demonstrates that this approach results in more realistic – and narrower – credible interval than the standard sensitivity analysis using confidence interval endpoints. In addition, the model permits incorporating data on the geographical distribution of reported case counts to create informative priors on the cumulative incidence to produce estimates and credible intervals for smaller geographic areas than often can be precisely estimated with seroprevalence surveys.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis methods study had no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study did not require IRB approval because it only used aggregate data already reported; the analysis did not use any individual-level data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for replicating the paper are provided in data tables. Statistical code is available at https://github.com/markjmeyer/BPA. https://github.com/markjmeyer/BPA